Xue Miao-Qun, Liu Jun, Sang Jian-Feng, Su Lei, Yao Yong-Zhong
Department of General Surgery, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
Department of General Surgery, The Jiang Bei People's Hospital of Nanjing, Nanjing 210048, China.
Oncotarget. 2017 Jul 25;8(30):48930-48937. doi: 10.18632/oncotarget.16893.
To investigate chemokine receptor CXCR1 expression characteristic in different breast tissues and analyze the relationship between CXCR1 expression changes in breast cancer tissue and efficacy of neo-adjuvant chemotherapy.
Chemokine receptor CXCR1 was lowly expressed in normal breast tissues and breast fibroadenoma, but highly expressed in breast cancer. It was significantly correlated with pathological stage, tumor cell differentiation, and lymph node metastasis (P < 0.05). After neo-adjuvant chemotherapy, CXCR1 expression in breast cancer tissues decreased. Among these 104 breast cancer patients with different molecular subtypes, the survival rate with Luminal A was the highest, followed by the Luminal B breast cancer, TNBC was the worst.
104 cases with breast carcinoma, 20 cases with normal breast and 20 cases with breast fibroadenoma were included and followed up. Immunohistochemistry was used to detect the expression of CXCR1 in the various tissues. The relationship between the CXCR1 expression changes in breast cancer biopsies and surgical specimens, as well as the efficacy of neo-adjuvant chemotherapy, was analyzed.
Chemokine receptor CXCR1 could be used as an indicator to predict benign or malignant breast disease, and it can even predict the malignancy degree of breast cancer, as well as its invasive ability and prognosis.
探讨趋化因子受体CXCR1在不同乳腺组织中的表达特征，并分析乳腺癌组织中CXCR1表达变化与新辅助化疗疗效之间的关系。
趋化因子受体CXCR1在正常乳腺组织和乳腺纤维瘤中低表达，而在乳腺癌中高表达。它与病理分期、肿瘤细胞分化及淋巴结转移显著相关（P<0.05）。新辅助化疗后，乳腺癌组织中CXCR1表达降低。在这104例不同分子亚型的乳腺癌患者中，Luminal A型的生存率最高，其次是Luminal B型乳腺癌，三阴性乳腺癌最差。
纳入104例乳腺癌患者、20例正常乳腺组织及20例乳腺纤维瘤患者并进行随访。采用免疫组织化学法检测各组织中CXCR1的表达。分析乳腺癌活检组织与手术标本中CXCR1表达变化以及新辅助化疗疗效之间的关系。
趋化因子受体CXCR1可作为预测乳腺疾病良恶性的指标，甚至可预测乳腺癌的恶性程度、侵袭能力及预后。
